Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Efficacy and safety of CAR-t cell therapy in richter transformation: A systematic review

Abdulrahman Al-Mashdali, Bassam Muthanna, Dina Soliman et al. Nov 03, 2025 pp. 8089-8089 10.1182/blood-2025-8089

Abstract Introduction: Richter transformation (RT), defined as the progression of chronic lymphocytic leukemia (CLL) into an aggressive lymp...

Implementing patient-centered PROMs in sickle cell disease care: A european consensus approach

Anna Collado Gimbert, Betzabel Cajiao Garcia, Raffaella Colombatti et al. Nov 03, 2025 pp. 2666-2666 10.1182/blood-2025-2666

Abstract Introduction Sickle cell disease (SCD) is a chronic disorder characterized by varied clinical outcomes, multi-o...

Dex and IL-7 enhance persistence of CAR T cells to promote long-term remission in mouse models of multiple myeloma

Ryan Urak, Alexandra Wolfarth, Donghoon Choi et al. Nov 03, 2025 pp. 5878-5878 10.1182/blood-2025-5878

Abstract Introduction: Chimeric antigen receptor (CAR) T cells have had phenomenal response rates in hematological malignancies, including &...

Risk of second primary malignancies among CLL survivors across treatment eras: A SEER-based study with racial and ethnic stratification

Chaitra Surapaneni, Ajay Kandra Nov 03, 2025 pp. 8025-8025 10.1182/blood-2025-8025

Abstract Introduction: Survivors of Chronic Lymphocytic Leukemia (CLL) are at increased risk of second primary malignancies (SPM). Treatment...

Concurrent viral infection as an adverse prognostic factor in diffuse large B-cell lymphoma, not otherwise specified

Haotian Wang, Jia Li, Luming Cao et al. Nov 03, 2025 pp. 3668-3668 10.1182/blood-2025-3668

Abstract Background and Objectives Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, exhibits high clin...

Etoposide-cytarabine-pegfilgrastim (EAP) and disease-specific chemotherapy regimens for hematopoietic stem cell mobilization in lymphoma: A randomized phase III trial

Peipei Ye, Renzhi Pei, Jie Jin et al. Nov 03, 2025 pp. 4182-4182 10.1182/blood-2025-4182

Abstract Background: Enough hematopoietic stem cell (HSC) collection is essential for successful autologous stem cell tr...

Qualitative interviews exploring the patient experience of fatigue in individuals with sickle cell disease (SCD), thalassemia, and pyruvate kinase (PK) deficiency

Biree Andemariam, NinaMaria Badalamenti, Rae Blaylark et al. Nov 03, 2025 pp. 7971-7971 10.1182/blood-2025-7971

Abstract Introduction: Hereditary hemolytic anemias (HHAs), including sickle cell disease (SCD), thalassemia, and pyruvate kinase (PK) defic...

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor

Audrey Bochi-Layec, Ivan Cohen, Jean Lemoine et al. Nov 03, 2025 pp. 4120-4120 10.1182/blood-2025-4120

Abstract Introduction: Systemic lupus erythematosus (SLE) is a serious autoimmune disease which chiefly involves B-cell dysregulation and ac...

Low-dose lenalidomide for maintenance of remission in primary central nervous system lymphoma: A single-center experience.

Michael Randall, Mazie Tsang, Chitoh Yung et al. Nov 03, 2025 pp. 900-900 10.1182/blood-2025-900

Abstract Background: Curative therapy for primary central nervous system lymphoma (PCNSL) consists of methotrexate-based induction therapy f...

Beyond TP53: Molecular IPSS-genes multihit status revisited

Marina Serra Carrera, Lorenzo Carita, Maria Gabarros-Subira et al. Nov 03, 2025 pp. 2090-2090 10.1182/blood-2025-2090

Abstract Introduction Molecular profiling has improved risk assessment in myelodysplastic syndromes (MDS), leading to th...

Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center

Mahesh Swaminathan, Alexandre Bazinet, Koji Sasaki et al. Nov 03, 2025 pp. 4634-4634 10.1182/blood-2025-4634

Abstract Introduction: The Area Deprivation Index (ADI), which measures neighborhood disadvantage using 17 socioeconomic factors, is a well-...

Single-cell transcriptomics reveals pathogenic interactions between clonal plasma cells and monocytes in POEMS syndrome

Xinli Han, Chi Li, Luyao Shi et al. Nov 03, 2025 pp. 3929-3929 10.1182/blood-2025-3929

Abstract Introduction: POEMS syndrome is a rare plasma cell disorder, primarily characterized by polyneuropathy, organomegaly, endocrinopathy...

Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study

Hannah Goulart, Elias Jabbour, Nitin Jain et al. Nov 03, 2025 pp. 1571-1571 10.1182/blood-2025-1571

Abstract Background The chemotherapy-free combination of blinatumomab (blina) and the potent pan-BCR-ABL tyrosine kinase inhibitor (TKI) pon...

Role of race in severity and survival of those with cutaneous T-cell lymphoma

Almeera Lateef, Pamela Allen, Darina Paulino et al. Nov 03, 2025 pp. 5428-5428 10.1182/blood-2025-5428

Abstract Background: Cutaneous T-Cell Lymphoma (CTCL) currently affects over 10.2 million people worldwide. Staphylococcal enterotoxin produ...

Pharmacokinetic (PK)-guided vs weight-based dosing of hydroxyurea for tanzanian children with sickle cell anemia

Luke Smart, Emmanuela Ambrose, Mwesige Charles et al. Nov 03, 2025 pp. 2959-2959 10.1182/blood-2025-2959

Abstract Introduction: Hydroxyurea titrated to achieve mild myelosuppression affords the greatest benefits for children with sickle cell ane...

Effect of GVHD prophylaxis on renal function and survival outcomes in allogeneic hematopoietic cell transplant patients with pre-existing renal impairment

Fnu Amisha, Jena Schmitz, Mariola Vazquez-Martinez et al. Nov 03, 2025 pp. 7764-7764 10.1182/blood-2025-7764

Abstract Background: Renal impairment (RI) is a common comorbidity identified during pre-transplant evaluation and is a well-established ris...

Standard transcranial doppler as a resource-efficient first step to screen for MRA-defined cerebral vasculopathy in adults with sickle cell disease

Olivier Pouliot, Jonathan St-Onge, Chrystelle Charles et al. Nov 03, 2025 pp. 4734-4734 10.1182/blood-2025-4734

Abstract Background Cerebral vasculopathy in sickle cell disease (SCD) is associated with thrombotic and hemorrhagic stroke. Magnetic resona...

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

Richard Miller, Ryan Wilcox, John Reneau et al. Nov 03, 2025 pp. 778-778 10.1182/blood-2025-778

Abstract Introduction ITK is expressed in T cells and NK cells and is involved in multiple signaling pathways including T cell receptor (TCR...

SPPL3-glycosylation axis governs CD22 CAR T-cell susceptibility in B-ALL independent of antigen recognition

Jaehyun Suh, Ukhyun Jo, Craig Thomas et al. Nov 03, 2025 pp. 2347-2347 10.1182/blood-2025-2347

Abstract Introduction: CD22-targeted chimeric antigen receptor (CAR) T-cell therapy has shown promising efficacy in relapsed/refractory B-ce...

Training program for DATA managers in hematopoietic cell transplantation and advanced cell therapy: A nine-year overview from Brazil

Cinthya Da Silva, Anderson João Simione, Flavia da Costa et al. Nov 03, 2025 pp. 4647-4647 10.1182/blood-2025-4647

Abstract Background: Until 2016, Brazil lacked a centralized registry for hematopoietic cell transplantation (HCT), limiting national outcom...

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study

Rakesh Popat, Niels W.C.J. van de Donk, Beth Faiman et al. Nov 03, 2025 pp. 5821-5821 10.1182/blood-2025-5821

Abstract Introduction: Talquetamab (Tal) is the first GPRC5D×CD3 bispecific antibody approved for the treatment of relapsed/refractory multi...

Overall survival and prognostic factors of adult patients with acute promyelocytic leukemia in the pre- all-trans-retinoic acid + arsenic trioxide (ATRA+ATO) era and the post-ATRA+ATO era in the US

Henry Becerra, Emmanuel Bugarin Estrada, Dosbai Saparov et al. Nov 03, 2025 pp. 8158-8158 10.1182/blood-2025-8158

Abstract Background Since late 1980s there were no significant therapeutic advances for Acute Promyelocytic Leukemia (APL)1. The results of...

Transfusion dependence is associated with poor survival in MDS-h and MDS-LB, while transplantation improves outcomes

Wenjing Guo, Linlin Liu, Li Jia et al. Nov 03, 2025 pp. 7381-7381 10.1182/blood-2025-7381

Abstract Hypoplastic myelodysplastic neoplasms (MDS-h) and MDS with low blasts (MDS-LB) are characterized by low blasts and absence of defin...

Trends and disparities in anemia and COPD-related mortality among adults in the United States from 1999 to 2023: A CDC wonder database analysis

Saif Rahman, Muhammad Ali, Alina Fatima et al. Nov 03, 2025 pp. 8008-8008 10.1182/blood-2025-8008

Abstract Introduction: Anemia and COPD are among the most common diseases in the United States, and when paired, accelerate morbidity and mo...

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

Liliana Lucca, Ossama Kohil, Marine Cuisinier et al. Nov 03, 2025 pp. 918-918 10.1182/blood-2025-918

Abstract Introduction Although the introduction of proteasome inhibitors, immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodie...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page